Sanofi ADR, based in Paris, France, is a leading global healthcare company committed to advancing the research, development, and production of innovative therapeutic solutions in specialty care, vaccines, and consumer healthcare. With a strong pipeline of biopharmaceutical products and a presence in over 100 countries, Sanofi is well-positioned to capitalize on growth opportunities in both developed and emerging markets, while effectively addressing critical unmet medical needs. The company's strategic focus on digital transformation and sustainability further enhances its competitive advantage, aligning with the interests of institutional investors focused on long-term value creation and responsible investment. Show more

Location: 46, AVENUE DE LA GRANDE ARMÉE, PARIS, FRANCE, 75017, Paris, 75017, USA | Website: https://www.sanofi.com | Industry: DRUG MANUFACTURERS - GENERAL | Sector: HEALTHCARE

Market Cap

114.3B

52 Wk Range

$44.62 - $57.57

Previous Close

$47.04

Open

$47.69

Volume

2,944,200

Day Range

$47.23 - $47.85

Enterprise Value

126.5B

Cash

7.657B

Avg Qtr Burn

N/A

Insider Ownership

0.00%

Institutional Own.

9.97%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Dupixent Details Chronic rhinosinusitis with nasal polyps	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Dupixent Details Chronic obstructive pulmonary disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Dupixent Details Chronic spontaneous urticaria	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Qfitlia™ (fitusiran) Details Hemophilia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TZIELD™ (PRV-031) (Teplizumab) Details Type 1 diabetes, Diabetes	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sarclisa® Details Multiple myeloma, Cancer	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Beyfortus™ (Nirsevimab- alip) Details Respiratory syncytial virus	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Dupixent Details Eosinophilic Esophagitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALTUVIIIO™ (Efanesoctocog alfa) Details Hemophilia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tolebrutinib Details Multiple sclerosis (MS)	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Amlitelimab Details Atopic dermatitis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ExPEC9V vaccine Details Invasive Extraintestinal Pathogenic Escherichia Coli Disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Frexalimab Details Autoimmune disease, Multiple sclerosis	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tzield (Teplizumab) Details Type 1 diabetes, Diabetes	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ordesekimab (PRV-015) (anti-IL-15) Details Celiac disease, Immune Disorders	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INBRX-101 (AAT-Fc fusion protein) Details Genetic disorder, Severe alpha-1 antitrypsin deficiency, Rare genetic disease, Emphysema due to Alpha-1 Antitrypsin Deficiency	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PRV-3279 Details Systemic lupus erythematosus, Autoimmune disease	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.